Comparison · NCT04372602-2118bdaa
Duvelisib vs Placebo: Viral Kinetics as Measured by Virologic Failure
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Duvelisib vs Placebo: Viral Kinetics as Measured by Virologic Failure. Trial comparisons, record NCT04372602-2118bdaa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04372602-2118bdaa
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.2 | 0.0705 | 0.452 | wilson | |
| Risk in group 2 | 0.385 | 0.177 | 0.645 | wilson | |
| Risk difference, group 1 minus group 2 | -0.185 | -0.475 | 0.142 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.52 | 0.153 | 1.77 | log | |
| Odds ratio, group 1 over group 2 | 0.4 | 0.074 | 2.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on Duvelisib than on Placebo | 5.42 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Duvelisib | -Duvelisib 25 mg twice daily for up to 10 days. | 3 | 15 | OG000 |
| Group 2 | Placebo | -Placebo 25 mg twice daily for up to 10 days. | 5 | 13 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Viral Kinetics as Measured by Virologic Failure
- Description
-Defined as increase in viral load of \>0.5 log on two consecutive days, or \>1 log increase in one day, not in keeping with any baseline trend of rising viral loads during the pre-treatment viral testing
- Time frame
- Through 28 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Duvelisib to Combat COVID-19
- NCT number
- NCT04372602
- Phases
- PHASE2
- Conditions
- COVID-19
- Interventions
- Duvelisib, Peripheral blood draw, Placebo
- Lead sponsor
- Washington University School of Medicine
- Results first posted
- 2023-03-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04372602?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04372602-2118bdaa